These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25913760)

  • 1. LX0702, a novel snake venom peptide derivative, inhibits thrombus formation via affecting the binding of fibrinogen with GPIIb/IIIa.
    Kong Y; Wang Y; Yang W; Xie Z; Li Z
    J Pharmacol Sci; 2015 Apr; 127(4):462-6. PubMed ID: 25913760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pyrrolidinoindoline alkaloid Psm2 inhibits platelet aggregation and thrombus formation by affecting PI3K/Akt signaling.
    Su XL; Su W; Wang Y; Wang YH; Ming X; Kong Y
    Acta Pharmacol Sin; 2016 Sep; 37(9):1208-17. PubMed ID: 27424653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tryptophan derivative TD-26 attenuates thrombus formation by inhibiting both PI3K/Akt signaling and binding of fibrinogen to integrin αIIbβ3.
    Chen Y; Wang Y; Xie Z; Ming X; Li Z; Kong Y
    Biochem Biophys Res Commun; 2015 Sep; 465(3):516-22. PubMed ID: 26278818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
    Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
    Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation.
    Li YX; Sun Q; Zhang H; Ren ST; Liao YR; Wang Y; Shen XL; Wang B
    Thromb Res; 2012 May; 129(5):e217-22. PubMed ID: 22445430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action.
    Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S
    Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
    Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors.
    Xie Z; Zhao L; Ding X; Kong Y; Li Z
    Future Med Chem; 2018 Feb; 10(4):367-378. PubMed ID: 29380625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates.
    Chen M; Ye X; Ming X; Chen Y; Wang Y; Su X; Su W; Kong Y
    Sci Rep; 2015 Jun; 5():10846. PubMed ID: 26035670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative.
    Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP
    Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aged garlic extract inhibits platelet activation by increasing intracellular cAMP and reducing the interaction of GPIIb/IIIa receptor with fibrinogen.
    Allison GL; Lowe GM; Rahman K
    Life Sci; 2012 Dec; 91(25-26):1275-80. PubMed ID: 23069586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.